These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16005141)

  • 1. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.
    Nagakawa O; Yamagishi T; Fujiuchi Y; Junicho A; Akashi T; Nagaike K; Fuse H
    Eur Urol; 2005 Oct; 48(4):686-90. PubMed ID: 16005141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer.
    Nagakawa O; Yamagishi T; Akashi T; Nagaike K; Fuse H
    Prostate; 2006 Apr; 66(5):447-52. PubMed ID: 16353247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
    Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H
    Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum keratinocyte growth factor measurement in patients with prostate cancer.
    Mehta PB; Robson CN; Neal DE; Leung HY
    J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Namba Y; Kishikawa H; Takahara S; Ichikawa Y
    Prostate Cancer Prostatic Dis; 2008; 11(3):258-63. PubMed ID: 17876341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
    Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
    Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression.
    Hara I; Miyake H; Yamanaka K; Hara S; Kamidono S
    Oncol Rep; 2002; 9(6):1379-83. PubMed ID: 12375052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of hepatocyte growth factor in patients with breast cancer.
    Sheen-Chen SM; Liu YW; Eng HL; Chou FF
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases.
    Wolff JM; Fandel TH; Borchers H; Jakse G
    Anticancer Res; 1999; 19(4A):2657-9. PubMed ID: 10470214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma.
    Tanaka K; Miki C; Wakuda R; Kobayashi M; Tonouchi H; Kusunoki M
    Scand J Gastroenterol; 2004 Aug; 39(8):754-60. PubMed ID: 15513361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
    Eaton CL; Wells JM; Holen I; Croucher PI; Hamdy FC
    Prostate; 2004 May; 59(3):304-10. PubMed ID: 15042606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
    Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
    J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression.
    Miyake H; Hara I; Eto H
    Anticancer Res; 2004; 24(4):2573-7. PubMed ID: 15330217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression.
    Housa D; Vernerova Z; Heracek J; Cechak P; Rosova B; Kuncova J; Haluzik M
    Neoplasma; 2008; 55(5):442-6. PubMed ID: 18665756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.
    Nam RK; Reeves JR; Toi A; Dulude H; Trachtenberg J; Emami M; Daigneault L; Panchal C; Sugar L; Jewett MA; Narod SA
    J Urol; 2006 Apr; 175(4):1291-7. PubMed ID: 16515983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
    Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM
    J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophage-stimulating protein.
    Kawaguchi M; Orikawa H; Baba T; Fukushima T; Kataoka H
    FEBS J; 2009 Jul; 276(13):3481-90. PubMed ID: 19456860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
    Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
    Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.